5月20日 - ** 在澳大利亚证券交易所上市的医疗设备制造商瑞思迈RMD.AX股价下跌7.3%至36.02澳元，创下自4月24日以来的最低水平。
** 该公司从事睡眠呼吸暂停、慢性阻塞性肺病和其他慢性疾病的治疗，其股价创下自3月12日以来的最大盘中跌幅。
** RMD 是 ASX 200 指数中跌幅最大的股票
** 竞争对手 Apnimed（未上市公司）宣布， (link)，治疗阻塞性睡眠呼吸暂停的口服药 AD109 的首个三期临床试验结果正面。
** 股价年初至今上涨 0.6
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.